Mercator Medical S.A., together with its subsidiaries, produces medical gloves and distributes medical disposables in Europe, Russia, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||zł166.10|
|52 Week High||zł145.20|
|52 Week Low||zł770.00|
|1 Month Change||-8.84%|
|3 Month Change||-26.99%|
|1 Year Change||-57.19%|
|3 Year Change||985.62%|
|5 Year Change||849.69%|
|Change since IPO||1,033.79%|
Recent News & Updates
Is Now The Time To Put Mercator Medical (WSE:MRC) On Your Watchlist?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Mercator Medical's (WSE:MRC) Promising Earnings May Rest On Soft Foundations
Mercator Medical S.A.'s ( WSE:MRC ) robust earnings report didn't manage to move the market for its stock. We did some...
|MRC||PL Medical Equipment||PL Market|
Return vs Industry: MRC underperformed the Polish Medical Equipment industry which returned -45.9% over the past year.
Return vs Market: MRC underperformed the Polish Market which returned 41.2% over the past year.
Stable Share Price: MRC is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MRC's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
Mercator Medical S.A., together with its subsidiaries, produces medical gloves and distributes medical disposables in Europe, Russia, and internationally. The company offers surgical gloves for conducting invasive surgeries that require sterile conditions; sterile examination and protective gloves for medical, outpatient, and diagnostic examinations, as well as therapeutic activities and working with septic materials; household gloves for use in gardening, housework, and food procedures; and protective and heavy-duty gloves. It also provides dressing products, such as gauze, non-woven fabric, non-woven cotton, sterile adhesive, and plaster dressing products, as well as medical adhesive tapes, elastic tubular bandages, absorption pads, and dialysis kits; and medical protective clothing, including caps, masks, medical coats and gowns, shoe covers, oversleeves, coveralls, scrub suits, and patients shirts.
Is Mercator Medical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MRC (PLN166.1) is trading below our estimate of fair value (PLN10858.15)
Significantly Below Fair Value: MRC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MRC is good value based on its PE Ratio (1.6x) compared to the European Medical Equipment industry average (39.9x).
PE vs Market: MRC is good value based on its PE Ratio (1.6x) compared to the Polish market (13.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MRC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MRC is good value based on its PB Ratio (1.3x) compared to the PL Medical Equipment industry average (3.5x).
How is Mercator Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mercator Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Mercator Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRC has a high level of non-cash earnings.
Growing Profit Margin: MRC's current net profit margins (47.2%) are higher than last year (26.3%).
Past Earnings Growth Analysis
Earnings Trend: MRC's earnings have grown significantly by 89.4% per year over the past 5 years.
Accelerating Growth: MRC's earnings growth over the past year (379.8%) exceeds its 5-year average (89.4% per year).
Earnings vs Industry: MRC earnings growth over the past year (379.8%) exceeded the Medical Equipment industry 59.7%.
Return on Equity
High ROE: MRC's Return on Equity (79%) is considered outstanding.
How is Mercator Medical's financial position?
Financial Position Analysis
Short Term Liabilities: MRC's short term assets (PLN1.4B) exceed its short term liabilities (PLN285.2M).
Long Term Liabilities: MRC's short term assets (PLN1.4B) exceed its long term liabilities (PLN9.1M).
Debt to Equity History and Analysis
Debt Level: MRC is debt free.
Reducing Debt: MRC has no debt compared to 5 years ago when its debt to equity ratio was 65.3%.
Debt Coverage: MRC has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MRC has no debt, therefore coverage of interest payments is not a concern.
What is Mercator Medical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MRC's dividend (0.3%) isn’t notable compared to the bottom 25% of dividend payers in the Polish market (2.13%).
High Dividend: MRC's dividend (0.3%) is low compared to the top 25% of dividend payers in the Polish market (6.02%).
Stability and Growth of Payments
Stable Dividend: MRC is not paying a notable dividend for the Polish market, therefore no need to check if payments are stable.
Growing Dividend: MRC is not paying a notable dividend for the Polish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MRC is not paying a notable dividend for the Polish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRC's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wieslaw Zyznowski (57 yo)
Dr. Wieslaw Zyznowski has been the Chairman of Management Board at Mercator Medical Spólka Akcyjna since 2010. In the 90s Dr. Zyznowski co-founded the Mercator. From 1991 to 2001 he served as (apart from a...
CEO Compensation Analysis
Compensation vs Market: Wieslaw's total compensation ($USD497.34K) is above average for companies of similar size in the Polish market ($USD320.03K).
Compensation vs Earnings: Wieslaw's compensation has increased by more than 20% in the past year.
Experienced Management: MRC's management team is considered experienced (2.7 years average tenure).
Experienced Board: MRC's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mercator Medical S.A.'s employee growth, exchange listings and data sources
- Name: Mercator Medical S.A.
- Ticker: MRC
- Exchange: WSE
- Founded: 1989
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: zł1.768b
- Shares outstanding: 10.65m
- Website: https://mercatormedical.eu
Number of Employees
- Mercator Medical S.A.
- Heleny Modrzejewskiej 30
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 17:03|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.